SCHEMBL6322658

SCHEMBL6322658

Cc1c(C(=O)N2CCN(C)CC2)c[nH]c1/C=C1\C(=O)Nc2cccc(-c3ccc(Br)cc3)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.47
FLT3 P36888 3/20 0.39
PDGFRB P09619 4/20 0.39
FGFR1 P11362 4/20 0.39
KDR P35968 4/20 0.39
ZAP70 P43403 1/20 0.39
CREBBP Q92793 1/20 0.39
CDK2 P24941 2/20 0.38
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
MET P08581 3/20 0.37
MEN1 O00255 1/20 0.37
CCNE1 P24864 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
PTK2B Q14289 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
AKT2 P31751 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322662 1.00 EGFR (0.47) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6320588 0.92 EGFR (0.49) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6320593 0.92 EGFR (0.49) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6321414 0.92 EGFR (0.48) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6321410 0.92 EGFR (0.48) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6324029 0.92 EGFR (0.51) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6321270 0.92 EGFR (0.52) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6321268 0.92 EGFR (0.52) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6324032 0.92 EGFR (0.51) EGFRFLT3PDGFRBFGFR1KDR
SCHEMBL6323469 0.90 EGFR (0.46) EGFRFLT3PDGFRBFGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 EGFR 367/4885FLT3 596/4885PDGFRB 575/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 EGFR 367/4885FLT3 596/4885PDGFRB 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.